Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.55 |
| ▸ | CHKA | P35790 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589309 | 0.85 | L3MBTL3 (0.47) | NCF1ALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL3590202 | 0.82 | AGXT (0.43) | NCF1CHKAALDH1A1GAAMAPT | |
| SCHEMBL4577411 | 0.82 | ALDH1A1 (0.56) | NCF1CHKAALDH1A1GAAMAPT | |
| SCHEMBL3451425 | 0.82 | CHKA (0.54) | NCF1CHKAALDH1A1GAAMAPT | |
| SCHEMBL12497577 | 0.81 | CHKA (0.47) | NCF1CHKAALDH1A1GAAMAPT | |
| SCHEMBL4181983 | 0.80 | AGXT (0.60) | ADRA2CCTSLCTSKCHEK1HTR2A | |
| SCHEMBL12496637 | 0.80 | MEN1 (0.50) | ALDH1A1GAAMAPTKDM4EKMT2A | |
| SCHEMBL3589553 | 0.80 | DRD2 (0.46) | CHKAMAPTKMT2AL3MBTL1CTSL | |
| SCHEMBL6487420 | 0.79 | KDM4E (0.63) | GAAKDM4EHTR2A | |
| SCHEMBL3594477 | 0.79 | LMNA (0.61) | NCF1CHKAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110467629-B | Benzoquinone derivative, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-110467629-A | Quinone derivatives, its pharmaceutical composition and application | SHANGHAI DE NOVO PHARMATECH CO LTD | 2019-11-19 | — | — | CN | disclosed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| CN-101516888-A | Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | disclosed |
| EP-2074127-A1 | PYRAZOLO [1, 5-A]PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20090099167-A1 | Organic compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH | 2009-04-16 | — | — | US | disclosed |
| CN-101394853-A | Use of pyrazolo [1, 5-a ] pyrimidin-7-ylamine derivatives in the treatment of neurological disorders | NOVARTIS AG (CH) | 2009-03-25 | — | — | CN | disclosed |
| US-20090069315-A1 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders | SIVASANKARAN RAJEEV | 2009-03-12 | — | — | US | disclosed |
| EP-1993552-A2 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008037459-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008037459-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| WO-2007103432-A9 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007103432-A2 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2007-09-13 | — | — | WO | disclosed |
| CN-1909908-A | Pyrazolo [1, 5-a ] pyrimidin-7-yl-amine derivatives for the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2007-02-07 | — | — | CN | disclosed |
| EP-1708710-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| US-20050222171-A1 | Organic compounds | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| WO-2005070431-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069315-A1 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders | EPHA5, EPHA7, EPHA1 | NCF1 3655/4885CHKA 480/4885ALDH1A1 578/4885 |
| US-20050222171-A1 | Organic compounds | JAK1, MAP3K5, MAP3K7 | NCF1 3776/4885CHKA 279/4885ALDH1A1 1515/4885 |
| US-20090099167-A1 | Organic compounds | JAK1, MAP3K5, MAP3K7 | NCF1 3776/4885CHKA 279/4885ALDH1A1 1515/4885 |
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | NCF1 623/4885CHKA 584/4885ALDH1A1 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.